Showing results (221-230 of 255) with videos related to

Sort By:
Pageof 26
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Science Translational Medicine|July 31, 2024
Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically ventilated patientsMarloes van den Berg, Zhonghua Shi, Wout J Claassen, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Science (New York, N.Y.)|March 19, 2011
Cardiac myosin activation: a potential therapeutic approach for systolic heart failureFady I Malik, James J Hartman, Kathleen A Elias, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Pageof 26